In ₹ Crore except Per Share Latest Annual	ZYDUSLIFE FY26	SUNPHARMA FY26	DRREDDY FY26	CIPLA FY26	Peer Average
Valuation — at last close
P/E	◆ 23.47×	36.77×	26.49×	28.43×	30.56× -23%
P/B	4.36×	5.05×	◆ 2.94×	3.20×	3.73× +17%
EV/EBITDA	◆ 14.78×	22.19×	17.19×	17.28×	18.89× -22%
Market Cap	₹1.18L Cr	₹4.22L Cr	₹1.12L Cr	₹1.10L Cr	₹2.14L Cr -45%
Growth
Revenue CAGR 3Y	◆ 16.35%	10.03%	10.96%	7.37%	9.45% +73%
Revenue CAGR 5Y	◆ 12.45%	11.78%	12.09%	8.01%	10.63% +17%
Net Income CAGR 3Y	◆ 34.80%	10.57%	-2.66%	10.88%	6.26% +456%
Revenue YoY (latest Q)	◆ 21.96%	10.46%	-1.48%	-2.44%	2.18% +907%
Net Income YoY (latest Q)	-34.90%	◆ 26.53%	-31.69%	-37.08%	-14.08% -148%
Profitability
EBITDA Margin	◆ 31.22%	30.33%	19.15%	20.89%	23.46% +33%
Net Income Margin	18.87%	◆ 19.69%	12.34%	13.71%	15.25% +24%
Return on Common Equity	◆ 19.74%	14.74%	11.75%	11.82%	12.77% +55%
Return on Capital Employed	◆ 21.79%	18.48%	11.30%	13.87%	14.55% +50%
Return on Assets	11.44%	◆ 11.46%	7.73%	9.67%	9.62% +19%
Credit & Quality
Total Debt/Equity	0.40×	0.05×	0.16×	◆ 0.01×	0.07× +445%
Interest Coverage	16.10×	43.65×	11.76×	◆ 85.90×	47.10× -66%
Scale — latest FY
Revenue / Total Income	₹27,148 Cr	₹58,462 Cr	₹33,700 Cr	₹28,163 Cr	₹40,108 Cr -32%
Net Income	₹5,124 Cr	₹11,509 Cr	₹4,158 Cr	₹3,862 Cr	₹6,509 Cr -21%
Total Assets	₹52,407 Cr	₹1.09L Cr	₹58,123 Cr	₹42,496 Cr	₹69,802 Cr -25%
EPS	₹50.09	₹47.8	₹50.41	₹48.03	₹48.75 +3%
Book Value per Share	₹269.5	₹348.31	₹453.79	₹426.24	₹409.45 -34%

◆ best value in the comp set per metric · Δ = subject vs average of the other companies.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.